Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

640
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
640

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.

Cancer research·2026
Same author

Quantifying single-cell responses to irradiation in 3D.

Frontiers in bioengineering and biotechnology·2026
Same author

Cell Cycle-Specific Regulation of Centrosome Clustering Dynamics in Cancer Cells by the Multifunctional Kinesin HSET.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Genetic resonance in the p53 signaling network.

Cell systems·2026
Same author

DNA damage checkpoints balance a tradeoff between diploid- and polyploid-derived arrest failures.

Cell reports·2025
Same author

Decoding the Central Dogma: Quantitative Insights into Transcription and Translation Dynamics in the p53-Mediated DNA Damage Response.

Journal of molecular biology·2025
Same journal

A native sulfur deposit in Gale crater, Mars.

Science (New York, N.Y.)·2026
Same journal

Coordinated demise of harmful algal blooms.

Science (New York, N.Y.)·2026
Same journal

Genetic effects put into context.

Science (New York, N.Y.)·2026
Same journal

Bacteria share proteins to survive antibiotics.

Science (New York, N.Y.)·2026
Same journal

Impacts shaped Earth's first continents.

Science (New York, N.Y.)·2026
Same journal

Erratum for the Report "Covalently bonded single-molecule junctions with stable and reversible photoswitched conductivity" by C. Jia <i>et al</i>.

Science (New York, N.Y.)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Mar 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Interacción dependiente del horario entre los tratamientos contra el cáncer

Sheng-Hong Chen1, William Forrester2, Galit Lahav1

  • 1Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

Science (New York, N.Y.)
|March 12, 2016
PubMed
Resumen
Este resumen es generado por máquina.

La inhibición del oncogén MDMX reactiva el supresor tumoral p53, pero su efecto sobre la muerte celular del cáncer depende de p53.

Más Videos Relacionados

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Videos de Experimentos Relacionados

Last Updated: Mar 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Área de la Ciencia:

  • En el campo de la oncología
  • Biología molecular
  • Señalización celular

Sus antecedentes:

  • El oncogén MDMX se sobreexpresa en muchos cánceres, suprimiendo el supresor tumoral p53.
  • Los inhibidores de MDMX pueden reactivar la p53 y mejorar la eficacia de los fármacos que dañan el ADN.
  • Falta una comprensión cuantitativa del efecto de la inhibición de MDMX en la señalización de p53 y la sensibilidad al daño del ADN.

Objetivo del estudio:

  • Investigar cuantitativamente cómo la inhibición de MDMX afecta la vía de señalización de p53.
  • Determinar el impacto de la inhibición de MDMX en la sensibilidad de las células cancerosas a los agentes que dañan el ADN.

Principales métodos:

  • La imagen de células vivas se empleó para observar la dinámica de acumulación de p53 en células individuales después del agotamiento de MDMX.
  • El estudio analizó las respuestas diferenciales de las células al daño del ADN durante distintas fases de acumulación de p53.

Principales resultados:

  • El agotamiento de MDMX indujo dos fases distintas de acumulación de p53: un pulso postmitótico inicial y subsecuentes oscilaciones de baja amplitud.
  • La respuesta celular al daño del ADN varió significativamente entre estas fases.
  • En la primera fase, el agotamiento de MDMX sinergizó con el daño del ADN para inducir la muerte celular.
  • En la segunda fase, el agotamiento de MDMX inhibió la muerte celular inducida por daño en el ADN.

Conclusiones:

  • El momento de la inhibición de MDMX en relación con el daño del ADN es crítico para los resultados terapéuticos.
  • Comprender la dinámica de la señal p53 y los estados celulares es esencial para optimizar las terapias combinadas.
  • Esta investigación proporciona una base cuantitativa para la programación de la administración dual de fármacos que incluyen inhibidores de MDMX y agentes que dañan el ADN.